Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Haemonetics Corporation (NYSE:HAE) by 43.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,569 shares of the medical instruments supplier’s stock after purchasing an additional 23,680 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned about 0.15% of Haemonetics worth $3,481,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HAE. Shine Investment Advisory Services Inc. purchased a new position in shares of Haemonetics during the 2nd quarter worth approximately $132,000. Riverhead Capital Management LLC grew its holdings in shares of Haemonetics by 79.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 1,507 shares during the period. Pacad Investment Ltd. purchased a new position in shares of Haemonetics during the 2nd quarter worth approximately $174,000. Shelton Capital Management purchased a new position in shares of Haemonetics during the 2nd quarter worth approximately $204,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Haemonetics during the 2nd quarter worth approximately $260,000.
A number of brokerages have recently commented on HAE. Zacks Investment Research cut Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, November 20th. Morgan Stanley increased their price target on Haemonetics from $43.00 to $51.00 and gave the company an “equal weight” rating in a report on Thursday, November 9th. Craig Hallum restated a “hold” rating and issued a $50.00 price objective (up from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Finally, Barrington Research upped their price objective on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $53.33.
Shares of Haemonetics Corporation (NYSE HAE) traded down $0.55 during trading on Thursday, hitting $56.56. The stock had a trading volume of 734,578 shares, compared to its average volume of 358,138. The stock has a market capitalization of $3,029.65, a price-to-earnings ratio of 35.19, a price-to-earnings-growth ratio of 4.31 and a beta of 0.99. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22. Haemonetics Corporation has a 52-week low of $36.44 and a 52-week high of $58.99.
Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.07. The business had revenue of $225.40 million during the quarter, compared to the consensus estimate of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.38 earnings per share. sell-side analysts forecast that Haemonetics Corporation will post 1.7 earnings per share for the current fiscal year.
In related news, Director Pedro P. Granadillo sold 7,118 shares of Haemonetics stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $57.06, for a total transaction of $406,153.08. Following the transaction, the director now directly owns 31,663 shares of the company’s stock, valued at $1,806,690.78. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Willaim P. Burke sold 13,193 shares of Haemonetics stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total transaction of $712,949.72. Following the transaction, the chief financial officer now directly owns 27,227 shares in the company, valued at $1,471,347.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,368 shares of company stock worth $2,602,393. Corporate insiders own 1.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Los Angeles Capital Management & Equity Research Inc. Has $3.48 Million Holdings in Haemonetics Corporation (NYSE:HAE)” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.thelincolnianonline.com/2017/12/07/haemonetics-corporation-hae-position-lifted-by-los-angeles-capital-management-equity-research-inc-updated-updated.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.